Boundless Bio, Inc. (BOLD)
2.63
+0.01
(+0.38%)
USD |
NASDAQ |
Oct 05, 13:42
Boundless Bio Net Income (Quarterly) : -23.69M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -23.69M |
| March 31, 2026 | -13.56M |
| December 31, 2025 | -12.88M |
| September 30, 2025 | -13.88M |
| June 30, 2025 | -15.68M |
| March 31, 2025 | -15.76M |
| December 31, 2024 | -16.45M |
| September 30, 2024 | -16.51M |
| Date | Value |
|---|---|
| June 30, 2024 | -16.98M |
| March 31, 2024 | -15.43M |
| December 31, 2023 | -12.14M |
| September 30, 2023 | -13.17M |
| June 30, 2023 | -12.40M |
| March 31, 2023 | -11.72M |
| December 31, 2022 | -11.78M |
| September 30, 2022 | -13.12M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 23.69M |
| EPS Diluted (Quarterly) | -1.055 |
| Enterprise Value | -13.74M |
| Earnings Yield | -108.6% |
| Normalized Earnings Yield | -108.57 |